AI assistant
Syncom Formulations (India) Ltd. Interim / Quarterly Report 2024
60987_rns_2024-08-12_9afac15c-ced3-4170-8d21-d323224c08d8.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
SYNCOM/SE/2024-25 12th August, 2024
Online filing at: www.listing.bseindia.com and https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp
To, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai (M.H.) 400 001 BSE CODE:524470
To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai- 400051 NSE SYMBOL: SYNCOMF
Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015- Submission of the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2024.
Dear Sir/Ma'am,
This is in continuation of our letter no. SYNCOM/SE/2024-25 dated 2nd August 2024 regarding intimation of Board meeting for consideration and approval of Quarterly Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2024.
Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2024, in PDF Format, which were also approved and recommended by the Audit Committee and further approved by the Board of Directors at their meeting held on Monday, 12 th August, 2024.
The Board Meeting was commenced at 4:00 P.M. and concluded at 4:30 P.M.
The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.
We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company.
You are requested to take on record the above said Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report for your reference and record.
Thanking You Yours Faithfully For, SYNCOM FORMULATIONS (INDIA) LIMITED
VAISHALI AGRAWAL Digitally signed by VAISHALI AGRAWAL Date: 2024.08.12 16:35:31 +05'30'
CS VAISHALI AGRAWAL COMPANY SECRETARY & COMPLIANCE OFFICER Encl: Unaudited Standalone and Consolidated Financial Results and Limited Review Report.
$\frac{1}{2}$
SYNCOM FORMULATIONS (INDIA) LIMITED
Regd.Off :- 7.Niraj Industrial Estate,Off Mahakali Caves Road.Andheri (E) Mumbai-400093
Works - 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- [email protected], Website:- www.sfil.in, CIN:- L24239MH1988PLC047759
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2024
| (Rs.In Lakhs) (Except EPS) | |||||
|---|---|---|---|---|---|
| S. No. |
Particulars | Quarter Ended | Year Ended | ||
| 30-06-2024 31-03-2024 |
30-06-2023 | 31-03-2024 | |||
| Unaudited | Audited* | Unaudited | Audited | ||
| $\mathbf{1}$ | Revenue from Operations | 8683.09 | 7326.63 | 5936.43 | 25835.96 |
| $\overline{2}$ | Other Income | 131.31 | 287.08 | 187.74 | 1310.06 |
| $\overline{3}$ | Total Income $(1 + 2)$ | 8814.40 | 7613.71 | 6124.17 | 27146.02 |
| $\overline{4}$ | EXPENSES | ||||
| (a) Cost of materials consumed (b) Purchases of Stock-in-Trade |
5303.13 | 3787.87 | 2265.31 | 13152.91 | |
| (c) Changes in inventories of finished goods, Stock-in-Trade and work-in-progress |
406.08 | 488.61 | 914.08 | 2620.83 | |
| (d) Employee benefits expense | (263.29) | (20.04) | 390.53 | (218.10) | |
| (e) Finance costs | 964.92 | 869.23 | 762.81 | 3505.77 | |
| (f) Depreciation and amortization expense | 38.65 | 116.97 | 112.17 | 444.87 | |
| g) Other expenses | 130.00 1225.22 |
129.77 | 110.00 | 472.23 | |
| Total expenses (4) | 7804.71 | 1320.45 6692.86 |
987.93 5542.83 |
3989.12 | |
| 5 | Profit/(loss) before exceptional items and tax (3-4) | 1009.69 | 920.85 | 581.34 | 23967.63 |
| 6 | Exceptional Items | 0.00 | 0.00 | 0.00 | 3178.39 (2.39) |
| $7\overline{ }$ | Profit/(loss) before tax (5 - 6) | 1009.69 | 920.85 | 581.34 | 3176.00 |
| 8 | Tax expense: | ||||
| (1) Current tax (2) Deferred tax |
243.77 | 241.73 | 160.30 | 758.25 | |
| 9 | Profit (Loss) for the period from continuing operations (7-8) | 3.06 | 4.27 | (3.81) | 55.43 |
| 762.86 | 674.85 | 424.85 | 2362.32 | ||
| 10 11 |
Profit/(loss) from discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 |
| 12 | Tax expense of discontinued operations Profit/(loss) from Discontinued operations (after tax) (10-11) |
0.00 | 0.00 | 0.00 | 0.00 |
| 0.00 | 0.00 | 0.00 | 0.00 | ||
| 13 | Profit/(loss) for the period (9+12) | 762.86 | 674.85 | 424.85 | 2362.32 |
| 14 | Other Comprehensive Income | ||||
| A(i)Items that will not be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | |
| (ii) Income tax relating to items that will not be reclassified to profit or loss |
|||||
| $B(i)$ Items that will be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | |
| (ii) Income tax relating to items that will be reclassified to profit | 275.93 | 164.57 | 206.77 | 681.39 | |
| or loss | 0.00 | 0.00 | 0.00 | 0.00 | |
| 15 | Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive |
||||
| Income for the period) | 1038.79 | 839.42 | 631.62 | 3043.71 | |
| 16 | Paid up Share Capital of the Company (Face Value 1/-) | 9400.00 | 9400.00 | 9400.00 | 9400.00 |
| 17 | Reserves excluding revaluation reserves | 19245.18 | |||
| 18 | Earnings per equity share (for continuing operation): | ||||
| $(1)$ Basic | 0.11 | 0.09 | 0.07 | 0.32 | |
| (2) Diluted | 0.11 | 0.09 | 0.07 | 0.32 | |
| 19 | Earnings per equity share (for discontinued operation): | ||||
| $(1)$ Basic (2) Diluted |
0.00 | 0.00 | 0.00 | 0.00 | |
| 20 | Earnings per equity share (for discontinued & continuing | 0.00 | 0.00 | 0.00 | 0.00 |
| operations) | |||||
| (1) Basic (2) Diluted |
0.11 0.11 |
0.09 0.09 |
0.07 0.07 |
0.32 0.32 |
Place: Indore Date: 12/08/2024
For, Syncom Formulations (India) Limited
Kedarmal Shankarlal Bankda Chairman & Wholetime Director DIN: 00023050
$\mathbf{L}$
COM
SYNCOM FORMULATIONS (INDIA) LIMITED
Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093
Works: - 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- [email protected], Website:- www sfil.in, CIN:- L24239MH1988PLC047759
| STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY RESULTS FOR THE QUARTER ENDED | 30TH JUNE 24 | ||||
|---|---|---|---|---|---|
| Quarter Ended | Year Ended | ||||
| S. No. | Particulars | 30-06-2024 | 31-03-2024 | 30-06-2023 | 31-03-2024 |
| Unaudited | Audited* | Unaudited | Audited | ||
| $\mathbf{1}$ | Segment Revenue | ||||
| a) Pharmaceuticals Drugs & Formulations | 8585.33 | 7302.70 | 5559.41 | 25,672.79 | |
| b) Trading of Commodities | 132.41 | 213.93 | 456.98 | 1,071.34 | |
| c) Renting of Property | 96.66 | 97.08 | 107.78 | 401.89 | |
| Total Segment Revenue | 8814.40 | 7613.71 | 6124.17 | 27,146.02 | |
| Less: Inter Segment Revenue | 0.00 | 0.00 | 0.00 | ||
| Revenue from Operations | 8814.40 | 7613.71 | 6124.17 | 27,146.02 | |
| $\overline{2}$ | Segment Results Profit(+)/Loss(-) before tax | ||||
| and interest from each segment | |||||
| a) Pharmaceuticals Drugs & Formulations | 955.36 | 939.46 | 595.98 | 3,232.76 | |
| b) Trading of Commodities | 4.39 | 19.92 | $-5.70$ | 18.49 | |
| c) Renting of Property | 88.59 | 78.44 | 103.23 | 369.62 | |
| Total Profit before tax | 1048.34 | 1037.82 | 693.51 | 3,620.87 | |
| Less: i) Interest | 38.65 | 116.97 | 112.17 | 444.87 | |
| ii) Other Un-allocable Expenditure | 0.00 | 0.00 | 0.00 | ||
| Profit before tax | 1009.69 | 920.85 | 581.34 | 3,176.00 | |
| $\mathbf{3}$ | (Segment Asset-Segment Liabilities) | ||||
| Segment Asset | |||||
| a) Pharmaceuticals Drugs & Formulations | 29437.25 | 33390.18 | 32038.86 | 33,390.18 | |
| b) Trading of Commodities | 964.42 | 1026.45 | 980.14 | 1,026.45 | |
| c) Renting of Property | 4733.45 | 4733.45 | 4733.45 | 4,733.45 | |
| Total Segment Asset | 35135.12 | 39150.08 | 37752.45 | 39,150.08 | |
| Un-allocable Assets | 0.00 | 0.00 | 0.00 | ||
| Net Segment Asset | 35135.12 | 39150.08 | 37752.45 | 39,150.08 | |
| Segment Liabilities | |||||
| a) Pharmaceuticals Drugs & Formulations | 5050.13 | 10181.37 | 11095.28 | 10,181.37 | |
| b) Trading of Commodities | 167.45 | 151.93 | 260.49 | 151.93 | |
| c) Renting of Property | 181.32 | 171.60 | 163.56 | 171.60 | |
| Total Segment Liabilities | 5398.90 | 10504.90 | 11519.33 | 10,504.90 | |
| Un-allocable Liabilities | 0.00 | 0.00 | 0.00 | ||
| Net Segment Liabilities | 5398.90 | 10504.90 | 11519.33 | 10,504.90 |
Notes:-
1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/08/2024
2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been conducted for the quarter ended on 30th June, 2024. The report does not have any impact on the above results and notes which needs explanation.
5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification
Place: Indore
Date: 12/08/2024
SANJAY MEHTA & ASSOGIATES
Ch artered Accountants
338, Saket Nagar, lndore - 452 018 (M.P.) Phone : 0731-2563625, 427439L,94250 62964 E-mail : [email protected]
Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Third Month ended 30th June, 2024 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015
To, The Board of Directors syNcoM FoRMULATIONS (lNDlA) LIMITED lndore (M P )
We have reviewed the accompanying statement of Standalone Unaudited Financial Results of SYNCOM FORMULATIONS (lNDlA) LIMITED ("the Comp3trY"), for the period ended June. 30. 2024 ("lhe Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
This staternent which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the lndian Accounting Standard 34 tnterim Frnancial Reporting" ("lND AS 34"), prescribed under Section 133 of the Companies Act. 2013 and other Accounting principles generally accepted in lndia and in compliance with the Regutation 33 of the SEBI (LODR) Regulations,2015, as amended, including relevant crrculars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of lnterim Financial lnformation performed by the tniefenaent Auditor of the Entity", issued by the lnstitute of Chartered Accountants of lndia. Thrs standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to rnquiries of company personnel and analytical procedures applied to financial data and thus provrde less assurance than an audit. We have not performed an audit and accordingly, we do trot express an audit opinion.
Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has noi disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it is to be disclosed, or that it contains any material misstatement.
For, Sanjay Mehta &Associates Chartered
FRN:01152 ffis W-2,
(Paftner) M. No. 079452 UDIN : 2407 9452BJZYYB4004
Place: lndore Date: 12th August, 2024
SYNCOM FORMULATIONS (INDIA) LIMITED
Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093
Works - 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- [email protected], Website:- www.sfil.in, CIN:- L24239MH1988PLC047759
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024
| (Rs.In Lakhs) (Except EPS) Quarter Ended |
|||||
|---|---|---|---|---|---|
| S. No. |
Particulars | Year Ended | |||
| 30-06-2024 | 31-03-2024 | 30-06-2023 | 31-03-2024 | ||
| Unaudited | Audited* | Unaudited | Audited | ||
| 1 | Revenue from Operations | 8725.54 | 7457.29 | 5983.58 | 26338.71 |
| $\overline{c}$ | Other Income | 133.84 | 309.84 | 187.47 | 1352.59 |
| $\overline{3}$ | Total Income $(1 + 2)$ | 8859.38 | 7767.13 | 6171.05 | 27691.30 |
| $\overline{4}$ | EXPENSES | 0.00 | |||
| (a) Cost of materials consumed | 5303.13 | 3787.87 | 2265.31 | 13152.91 | |
| b) Purchases of Stock-in-Trade | 428.61 | 501.95 | 921.42 | 2710.59 | |
| (c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress |
(280.40) | (20.04) | 368.22 | (175.46) | |
| (d) Employee benefits expense | 964.92 | 869.23 | 762.81 | 3505.77 | |
| (e) Finance costs | 39.03 | 119.51 | 112.17 | 447.41 | |
| (f) Depreciation and amortization expense | 130.00 | 129.77 | 110.00 | 472.23 | |
| (g) Other expenses | 1263.88 | 1375.84 | 1019.85 | 4180.16 | |
| Total expenses (4) | 7849.17 | 6764.13 | 5559.78 | 24293.61 | |
| 5 | Profit/(loss) before exceptional items and tax (3-4) | 1010.21 | 1003.00 | 611.27 | 3397.69 |
| 6 | Exceptional Items | 0.00 | 0.00 | 0.00 | (2.39) |
| $\overline{7}$ | Profit/(loss) before tax (5 - 6) | 1010.21 | 1003.00 | 611.27 | 3395.30 |
| 8 | Tax expense: | 0.00 | |||
| (1) Current tax | 243.90 | 258,28 | 175.45 | 808.45 55.43 |
|
| (2) Deferred tax Profit (Loss) for the period from continuing operations (7-8) |
3.06 | 4.27 | (3.81) | ||
| $\overline{9}$ | 763.25 | 740.45 | 439.63 | 2531.42 | |
| 10 | Profit/(loss) from discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 |
| 11 | Tax expense of discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 |
| 12 | Profit/(loss) from Discontinued operations (after tax) (10-11) | 0.00 | 0.00 | 0.00 | 0.00 |
| 13 | Profit/(loss) for the period $(9 + 12)$ | 763.25 | 740.45 | 439.63 | 2531.42 |
| 14 | Other Comprehensive Income | ||||
| A(i) Items that will not be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | |
| (ii) Income tax relating to items that will not be reclassified to profit | |||||
| or loss B (i) Items that will be reclassified to profit or loss |
0.00 | 0.00 | 0.00 | 0.00 681.39 |
|
| (ii) Income tax relating to items that will be reclassified to profit or | 275.93 | 164.57 | 206.77 | ||
| loss | 0.00 | 0.00 | 0.00 | 0.00 | |
| CI | Total Comprehensive Income for the period (XIII+XIV) | ||||
| (Comprising Profit (Loss) and Other Comprehensive Income for | 1039.18 | 905.02 | 646.40 | 3212.81 | |
| the period) Paid up Share Capital of the Company (Face Value 1/-) |
9400.00 | 9400.00 | 9400.00 | 9400.00 | |
| 16 17 |
Reserves excluding revaluation reserves | 19414.28 | |||
| 18 | Earnings per equity share (for continuing operation): | ||||
| $(1)$ Basic | 0.11 | 0.10 | 0.07 | 0.34 | |
| (2) Diluted | 0.11 | 0.10 | 0.07 | 0.34 | |
| 19 | Earnings per equity share (for discontinued operation): | ||||
| $(1)$ Basic | 0.00 | 0.00 | 0.00 | 0.00 | |
| (2) Diluted | 0.00 | 0.00 | 0.00 | 0.00 | |
| 20 | Earnings per equity share (for discontinued & continuing operations) | ||||
| $(1)$ Basic | 0.11 | 0.10 | 0.07 | 0.34 | |
| (2) Diluted | 0.11 | 0.10 | 0.07 | 0.34 |
Place: Indore
For, Syncom Formulations
Date: 12/08/2024
Kedarmal Shankarlaf Bankda Chairman & Wholetime Director DIN: 00023050
SYNCOM FORMULATIONS (INDIA) LIMITED
Regd.Off :- 7 Niraj Industrial Estate Off Mahakali Caves Road, Andheri (E) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- [email protected], Website:- www.sfil.in, CIN:- L24239MH1988PLC047759
| Quarter Ended | Year Ended | ||||
|---|---|---|---|---|---|
| S. No. | Particulars | 30-06-2024 | 31-03-2024 | 30-06-2023 | 31-03-2024 |
| Unaudited | Audited* | Unaudited | Audited | ||
| $\mathbf{1}$ | Segment Revenue | ||||
| a) Pharmaceuticals Drugs & Formulations | 8630.31 | 7454.52 | 5606.59 | 26,218.06 | |
| b) Trading of Commodities | 132.41 | 213.93 | 456.98 | 1,071.34 401.89 |
|
| c) Renting of Property | 96.66 | 98.67 | 107.48 | ||
| Total Segment Revenue | 8859.38 | 7767.12 | 6171.05 | 27,691.29 | |
| Less: Inter Segment Revenue | 0.00 | 0.00 | 0.00 | ||
| Revenue from Operations | 8859.38 | 7767.12 | 6171.05 | 27,691.29 | |
| $\overline{2}$ | Segment Results Profit(+)/Loss(-) before tax and interest from each segment |
||||
| a) Pharmaceuticals Drugs & Formulations | 956.25 | 1022.55 | 626.21 | 3,454.60 | |
| b) Trading of Commodities | 4.39 | 19.92 | $-5.70$ | 18.49 | |
| c) Renting of Property | 88.59 | 80.03 | 102.93 | 369.62 | |
| Total Profit before tax | 1049.23 | 1122.50 | 723.44 | 3,842.71 | |
| Less: i) Interest | 39.03 | 119.51 | 112.17 | 447.41 | |
| ii) Other Un-allocable Expenditure | 0.00 | 0.00 | |||
| Profit before tax | 1010.20 | 1002.99 | 611.27 | 3,395.30 | |
| $\overline{3}$ | (Segment Asset-Segment Liabilities) | ||||
| Segment Asset | |||||
| a) Pharmaceuticals Drugs & Formulations | 29849.25 | 34706.49 | 32085.85 | 34,706.49 | |
| b) Trading of Commodities | 964.42 | 1026.45 | 980.14 | 1,026.45 | |
| c) Renting of Property | 4733.45 | 4733.45 | 4733.45 | 4.733.45 | |
| Total Segment Asset | 35547.12 | 40466.39 | 37799.44 | 40,466.39 | |
| Un-allocable Assets | 0.00 | 0.00 | 0.00 | ||
| Net Segment Asset | 35547.12 | 40466.39 | 37799.44 | 40,466.39 | |
| Segment Liabilities | |||||
| a) Pharmaceuticals Drugs & Formulations | 5241.86 | 11328.58 | 11127.46 | 11,328.58 | |
| b) Trading of Commodities | 167.45 | 151.93 | 260.49 | 151.93 | |
| c) Renting of Property | 181.32 | 171.60 | 163.56 | 171.60 | |
| Total Segment Liabilities | 5590.63 | 11652.11 | 11551.51 | 11,652.11 | |
| Un-allocable Liabilities | 0.00 | 0.00 | 0.00 | ||
| Net Segment Liabilities | 5590.63 | 11652.11 | 11551.51 | 11,652.11 |
Notes:-
1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/08/2024.
2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time
3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been conducted for the quarter ended on 30th June, 2024. The report does not have any impact on the above results and notes which needs explanation.
5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
Place: Indore
Date: 12/08/2024
For, Syncom Formulations sarlal Ban Kedarmal S Chairman & W
SANJAY MEHTA & ASSOGIATES
CharteredAccountants
338, Saket Nagar, lndore - 452 018 (M'P') Phone : O73t-2563625, 427439L,94250 62964 E-mail : office@smaonline'in
Limitecl Review Report on Un-audited Consolidated Financial Results for the Quarter and 'l-hree Months ended 30tr'June,202J pursuant to Regulation 33 of the SEBI (LODR) Regulations. :fll5
To. The Board of Directors SYNCOM FORMULATIONS (INDIA) LITIITED Inclore (M.P )
- L We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of SYNCOM FORMULATIONS (l\DL{) LI}IITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together retbrred to as "the Croup"), fbr the period ended June 30, 2024 (the Statement"). anached hereu'ith. being submitted by the Cornpany pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations,2015. as amended inclLrding relerant circular issued by the SEBI fiom tirne to time.
- This staternent which is the responsibility of the Companl's Management and has been approved by the Cornpany's Board of Directors. has been prepared in accordance with the recognition and measuremeht principles laid dorvn in the Indian Accounting Standard 34 Interim Financial Reporting" ("[ND AS 3,1"), prescribed under Section 133 of the Cornpanies Act,20l3, and other Accounting principles generally accepted in lndia and in compliance with tlre Regulation 33 of the SEBI (LODR) Regulations,2015, as arnended, including relevant circulars issued by'the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review. 2.
- We conducted our revierv of the Staternent in accordance with the Standard on Review [:rrgsgc.nrents (SRE) 241 0. "Re,r,iew o.f Inlerim Finuncittl In/itrmalirtn perfbrmed b1t the lntlapcntlent .lutlitor o/ the Entitv", i,ssuctl by the Institute of Chartered Accountants of lndia. This standard requires that we plan and perfbrrn the review tct obtain moderate assurance as to whether the t-irrancial statements are free of rnaterial misstatement. A revierv is lirnited prirnarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not perfbrmed an audit and accordingly, we do ttot express an audit opiniort.
| S. No. | Name of the Company | Relationship with the tlolding Company |
|---|---|---|
| I | Santa Biotech Pvt. Ltd. | Whollv Owned Subsidi |
| 2. | Synrnex Phelnq I']r'_t. L14 | Whollv Owned Subsidiary |
| J. | Vincit Bioteclr International P.',t. | Wholly Owned Subsidiarl |
- The Statement includes the results of the fbllowing entity:
- Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Place: Indore Date: 12th August 2024
For, Sanjay Mehta & Associates Chartered Accountants FRN: 011524C INDORE ⋩ CA Manish Mittal (Partner) M. No. 079452 UDIN: 24079452BJZYYC1987
we have well not been as readow an image moderate more all since parts are and no should inspire should be